Search Results

Matinas BioPharma Holdings, Inc. announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.

Matinas BioPharma Holdings, Inc. announces that James J. Ferguson, M.D., Chief Medical Officer of Matinas, will be presenting two abstracts at the ASGCT 27th Annual Meeting being held May 7-11, 2024 in Baltimore highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of Matinas’ LNC platform for the uptake and targeted delivery of small oligonucleotides.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces positive results from an additional in vivo study in healthy mice with an oral LNC formulation of docetaxel, a well-established chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors.

Matinas BioPharma Holdings, Inc. announces positive results from an in vivo animal study of an oral LNC formulation of docetaxel, a well-known chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors.

Matinas BioPharma Holdings, Inc. announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2023 financial results and provides a business update.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Matinas BioPharma provided an update from its ongoing Compassionate/Expanded Use Access Program with MAT2203, the Company’s proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B.